Compare RAAQ & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAAQ | NTHI |
|---|---|---|
| Founded | 2024 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.3M | 221.5M |
| IPO Year | 2025 | N/A |
| Metric | RAAQ | NTHI |
|---|---|---|
| Price | $10.27 | $9.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.8K | ★ 69.8K |
| Earning Date | 01-01-0001 | 02-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.62 | $3.20 |
| 52 Week High | $10.83 | $25.00 |
| Indicator | RAAQ | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.39 |
| Support Level | N/A | $9.05 |
| Resistance Level | N/A | $10.05 |
| Average True Range (ATR) | 0.00 | 0.89 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 46.53 |
Real Asset Acquisition Corp is a blank check company.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).